ASHP: Joint Commission Impact on Pain Management Discussed

Share this content:
ASHP: Joint Commission Impact on Pain Management Discussed
ASHP: Joint Commission Impact on Pain Management Discussed

TUESDAY, Dec. 5, 2017 (HealthDay News) -- Insights into the impact of The Joint Commission's standards on pain management were presented during an educational session held at the mid-year clinical meeting and exhibition of the American Society of Health-System Pharmacists, held from Dec. 3 to 7 in Orlando, Fla.

During the session, David W. Baker, M.D., M.P.H., of The Joint Commission, provided insight into trends in opioid prescriptions over the last three decades and discussed the history of pain management standards, as well as current quality and safety problems in acute pain management, especially opioid prescribing. In addition, he also presented an overview of the revised standards and how they can build the framework for an opioid stewardship program.

The session outlined current issues associated with management of pain, including limited screening for opioid use or addiction history, lack of assessment for respiratory depression, opioid off-label use, lack of prescribing pattern monitoring, and lack of patient education on addiction potential and side effects. The new and revised standards from The Joint Commission were published in July 2017 to address some of the issues associated with over-prescribing and lack of monitoring. They aim to provide clinical practitioners with a framework to ensure safe pain medication prescribing through leadership, hospital and patient education, prescription monitoring and tracking, and drug diversion and disposal recommendations.

"Pain assessment and pain management, including safe opioid prescribing, is identified as an organizational priority for the hospital," Baker said during the session.

Presentation Slides
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »